MiR-17- 5p/RRM2 regulated gemcitabine resistance in lung cancer A549 cells

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018 Oct;52(Pt 1):103–109.
   PubMed Web of Science ®Google Scholar
• Fang C-L, Guo L-L. Research situation of miRnas in regulating chemotherapy resistance of lung cancer. Chin J Cancer Prev Treat. 2014;21(01):72–76.
   Google Scholar
• Siegel RL, Miller KD, Fuchs HE. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Shi W-C, Liu X-M. Research progress on the drug resistance mechanism of gemcitabine in the treatment of non-small cell lung cancer. Chin J Lung Diseases (electronic Edition). 2013;6(6):557–559.
   Google Scholar
• Liu Q, Yu S, Zhao W, et al. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018 Feb 19;17(1):53.
   PubMedGoogle Scholar
• Wanigasooriya K, Tyler R, Barros-Silva JD, et al. Radiosensitising cancer using phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or mammalian target of rapamycin (mTOR) Inhibitors. Cancers (Basel). 2020 May 18;12(5). DOI:10.3390/cancers12051278
   PubMed Web of Science ®Google Scholar
• Sastry SK, Elferink LA. Checks and balances: interplay of RTKs and PTPs in cancer progression. Biochem Pharmacol. 2011 Sep 1;82(5):435–440.
   PubMed Web of Science ®Google Scholar
• Burris HA. 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013 Apr;71(4):829–842.
   PubMed Web of Science ®Google Scholar
• Liang AL, Du SL, Zhang B, et al. Screening miRnas associated with resistance gemcitabine from exosomes in A549 lung cancer cells. Cancer Manag Res. 2019;11:6311–6321.
   PubMed Web of Science ®Google Scholar
• Li L, He L, Zhao JL, et al. MiR-17-5p up-regulates YES1 to modulate the cell cycle progression and apoptosis in ovarian cancer cell lines. J Cell Biochem. 2015 Jun;116(6):1050–1059.
   PubMed Web of Science ®Google Scholar
• Dhar S, Kumar A, Rimando AM, et al. Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget. 2015;6(29):27214–27226.
   PubMed Web of Science ®Google Scholar
• Gong A-Y, Eischeid AN, Xiao J, et al. MiR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer. 2012;12:492.
   PubMed Web of Science ®Google Scholar
• Meng L-J, Wang J, Fan W-F, et al. Effects of miR-17-5P on the proliferation and invasion of lung cancer cell lines A549, SPCA-1 and GLC-82. Chin J Surg Oncol. 2015;7(05):282–286.
   Google Scholar
• Lu H, Lu S, Yang D, et al. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Biosci Rep. 2019 May 31;39(5). DOI:10.1042/BSR20181374
   Google Scholar
• Mah V, Alavi M, Márquez-Garbán DC, et al. Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. PLoS ONE. 2015;10(5):e0127600.
   PubMed Web of Science ®Google Scholar
• Grolmusz VK, Karászi K, Micsik T, et al. Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. Am J Cancer Res. 2016;6(9):2041–2053.
   PubMed Web of Science ®Google Scholar
• Jin CY, Du L, Nuerlan AH, et al. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging. 2020 Dec 19;13(3):3518–3535.
   PubMedGoogle Scholar
• Zhao Y, Zheng Y, Zhu Y, et al. M1 macrophage-derived exosomes loaded with gemcitabine and deferasirox against chemoresistant pancreatic cancer. Pharmaceutics. 2021 Sep 17;13(9). DOI:10.3390/pharmaceutics13091493
   Web of Science ®Google Scholar
• Fagundes R, Teixeira LK. Cyclin E/CDK2: dNA replication, replication stress and genomic instability. Front Cell Dev Biol. 2021;9:774845.
   PubMed Web of Science ®Google Scholar
• Chu C, Geng Y, Zhou Y, et al. Cyclin E in normal physiology and disease states. Trends Cell Biol. 2021 Sep;31(9):732–746.
   PubMed Web of Science ®Google Scholar
• Suski JM, Braun M, Strmiska V, et al. Targeting cell-cycle machinery in cancer. Cancer Cell. 2021 Jun 14;39(6):759–778.
   PubMed Web of Science ®Google Scholar
• Tadesse S, Anshabo AT, Portman N, et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today. 2020 Feb;25(2):406–413.
   PubMed Web of Science ®Google Scholar
• Loukil A, Cheung CT, Bendris N, et al. Cyclin A2: at the crossroads of cell cycle and cell invasion. World J Biol Chem. 2015 Nov 26;6(4):346–350.
   PubMedGoogle Scholar
• Li J, Chen Y, Wang X, et al. CDCA2 triggers in vivo and in vitro proliferation of hepatocellular carcinoma by activating the AKT/CCND1 signaling. J Buon. 2021 May-Jun;26(3):882–888.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005 Nov;30(11):630–641.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Kaida D. CCNE1 and E2F1 partially suppress G1 phase arrest caused by spliceostatin a treatment. Int J Mol Sci. 2021 Oct 27;22(21):11622–11632.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhu Q, Gu J, et al. Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin. Biosci Rep. 2019 Jun 28;39(6). DOI:10.1042/BSR20190381
   Google Scholar
• Zhou JS, Yang ZS, Cheng SY, et al. MiRNA-425-5p enhances lung cancer growth via the PTEN/PI3K/AKT signaling axis. BMC Pulm Med. 2020 Aug 24;20(1):223–229.
   PubMed Web of Science ®Google Scholar
• Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017 Apr 20;169(3):381–405.
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004 Apr;30(2):193–204.
   PubMed Web of Science ®Google Scholar
• Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res. 2010 Jan 1;2(1):19–42.
   PubMed Web of Science ®Google Scholar
• Shah KN, Mehta KR, Peterson D, et al. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition. Mol Cancer Res. 2014 Mar;12(3):394–407.
   PubMed Web of Science ®Google Scholar
• Xu YJ, Wei RS, Li XH, et al. MiR-421 promotes lipid metabolism by targeting PTEN via activating PI3K/AKT/mTOR pathway in non-small cell lung cancer. Epigenomics. 2022 Jan 20;14:121–138.
   Web of Science ®Google Scholar